2020
DOI: 10.1101/2020.12.23.424167
|View full text |Cite
Preprint
|
Sign up to set email alerts
|

Multiplexed experimental strategies for fragment library screening using SPR biosensors

Abstract: Surface plasmon resonance biosensor technology (SPR) is ideally suited for fragment-based lead discovery. However, generally suitable experimental procedures or detailed protocols are lacking, especially for structurally or physico-chemically challenging targets or when tool compounds are lacking. Success depends on accounting for the features of both the target and the chemical library, purposely designing screening experiments for identification and validation of hits with desired specificity and mode-of-act… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

0
3
0

Year Published

2021
2021
2023
2023

Publication Types

Select...
2

Relationship

1
1

Authors

Journals

citations
Cited by 2 publications
(3 citation statements)
references
References 38 publications
0
3
0
Order By: Relevance
“…A structurally diverse fragment library comprised of 1056 compounds including 3D fragments 29 was screened against WT and engineered AChBP variants. The screening cascade was split into three distinct experiments ( Fig.…”
Section: Resultsmentioning
confidence: 99%
“…A structurally diverse fragment library comprised of 1056 compounds including 3D fragments 29 was screened against WT and engineered AChBP variants. The screening cascade was split into three distinct experiments ( Fig.…”
Section: Resultsmentioning
confidence: 99%
“…Guo et al have found that the detection of HE4 using Luminex was elevated in only 12% of early-stage EOC cases and 36% of late-stage cases [72]. Furthermore, labeled multiplex immunoassay formats may struggle to accurately identify complex antibodies and differentiate between different antibody complexes [57,83,84]. This is attributed to the inconsistent affinity and stability of target analytes in multiplex assays that utilize monoclonal antibodies [76,85].…”
Section: The Technologiesmentioning
confidence: 99%
“…A comparison of Luminex and PEA technology, highlighting their respective limitations[36,70,[81][82][83]88,89].…”
mentioning
confidence: 99%